Innovation in the stock market is often good business

Scopri di più

“Eccedi le aspettative dei tuoi clienti. Dagli quello di cui hanno bisogno e qualcosa di più.”

Sam Walton, fondatore di Walmart

Scopri di più

Good Stocks: Innovation in the stock market is often good business


Fintech, Industry 4.0, artificial intelligence, biotechnology, robotics, augmented reality and more. In this column we discover some of the most interesting companies operating in high-tech sectors. Today we are pervaded by devices and technologies that are able to radically change, within a few years, the way we are accustomed to move, communicate and spend our free time.


More and more often we happen to read or hear about news about new medical discoveries, new production methods, new services. For this reason, what we are going to discuss in this article (and in the next ones) could be a good way to get a general overview of the potential players that will shape the world as we know it today.




Founded in 1985 by James E. Heppelmann in Boston, Massachusetts, PTC (Parametric Technology Corporation) is a software and services company that enables, through its devices and technology, not only to closely relate the real world to the digital world, transforming the way products are engineered and manufactured, but also to generate and channel data continuously across multiple departments, fostering collaboration on multiple levels and giving individuals greater power and control over the entire industrial process.


PTC tools can be applied in the high-tech, automotive, aerospace or medical device manufacturing industries. They can reduce operating costs and maximize revenue growth by streamlining various production processes. For this reason, the company is positioned among the major players in the Industry 4.0 sector.


PTC Inc. market share NASDAQ (Ticker: PTC)




The Jacksonville, Florida-based company was born on June 1, 2020 from the merger of two acquisitions by AE Industrial Partners (a private equity firm specializing in aerospace, defense services and energy production): Adcole Space and Deep Space Systesm (DSS). The latter specializes in the design, development, integration, testing and operation of advanced space systems, components and spacecraft. Adcole Space, on the other hand, was founded in 1957 and has been a major player in space exploration since its inception, providing its know-how in many space voyages to Mercury, Mars, Jupiter, Saturn and Pluto.


The combination of the two is aimed at making Redwire a leader in the future of space infrastructure, with the goal of accelerating humanity's expansion beyond Earth's borders by developing reliable, affordable and sustainable solutions for future generations.


Redwire, in part through its recent acquisition of Made in Space (MIS), a leader in in-orbit additive manufacturing, is revolutionizing the way in which various space infrastructures, including Low Earth Orbit (LEO) satellites, are manufactured using cutting-edge technologies capable of creating components directly in space.


Redwire Corp. listed on the NYSE (Ticker: RDW)



CRISPR Therapeutics


CRISPR Therapeutics is a Zurich-based biotechnology company focused on developing innovative medicines through genomic editing. This new gene therapy is based on the direct genetic engineering of DNA, in which the information contained in it is modified, inserted, deleted or replaced, manipulating individual components.


This is made possible thanks to the CRISPR/Cas9 system, in which the Cas9 protein is used, a kind of molecular scissors capable of cutting a specifically identified area of DNA, with the aim of modifying the genome and any imperfections present, eliminating harmful DNA sequences or correcting mutations that cause diseases.


The company has in its pipeline a series of therapeutic programs that include the use of this new technique alongside oncology and regenerative medicine, to counteract the onset or proliferation of several rare diseases. To accelerate and augment its efforts, CRISPR Therapeutics has entered into strategic collaborations with a number of pharmaceutical companies including Vertex, ViaCyte and Bayer AG.


Together with Vertex, it is developing a therapy, currently in late clinical stages, that seeks to treat sickle cell anemia (a severe inherited genetic hemoglobin disorder).


CRISPR Therapeutics AG, listed on the NASDAQ market (Ticker: CRSP) and the Frankfurt market (Ticker: 1CG)